113 related articles for article (PubMed ID: 25219752)
1. The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.
Tao C; Lin H; Chen S
Gene; 2014 Nov; 552(1):106-15. PubMed ID: 25219752
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib regulating ERK signals pathway in gastric cancer cell.
Juan LW; En LM; Hao L; Kai HY; Ju H
Environ Toxicol Pharmacol; 2014 Sep; 38(2):438-43. PubMed ID: 25136776
[TBL] [Abstract][Full Text] [Related]
3. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J
Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619
[TBL] [Abstract][Full Text] [Related]
4. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Chen G; Nicula D; Renko K; Derwahl M
Oncol Rep; 2015 Apr; 33(4):1994-2000. PubMed ID: 25683253
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression.
Huang YS; Xue Z; Zhang H
Med Oncol; 2015 Feb; 32(2):470. PubMed ID: 25579168
[TBL] [Abstract][Full Text] [Related]
6. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
[TBL] [Abstract][Full Text] [Related]
7. [Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
Chen FS; Cui YZ; Luo RC; Wu J; Zhang H
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1684-7. PubMed ID: 18819900
[TBL] [Abstract][Full Text] [Related]
8. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Yang Q; Zhang S; Kang M; Dong R; Zhao J
Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
[TBL] [Abstract][Full Text] [Related]
9. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
10. Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Zhang YN; Wu XY; Zhong N; Deng J; Zhang L; Chen W; Li X; Zhong CJ
Mol Med Rep; 2014 Jan; 9(1):365-9. PubMed ID: 24213303
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
13. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.
Zhao W; Gu YH; Song R; Qu BQ; Xu Q
Leukemia; 2008 Jun; 22(6):1226-33. PubMed ID: 18337760
[TBL] [Abstract][Full Text] [Related]
15. Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma.
Hu W; Yuan Q; Liu XH; Zhu HC; Lv SQ; Wang XH
Eur J Pharmacol; 2015 Feb; 749():142-50. PubMed ID: 25614335
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Biochem; 2013 Aug; 114(8):1819-31. PubMed ID: 23463670
[TBL] [Abstract][Full Text] [Related]
17. VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
Mei J; Zhu X; Wang Z; Wang Z
Cell Biochem Biophys; 2014 May; 69(1):151-6. PubMed ID: 24375110
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
20. The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
Mao WF; Shao MH; Gao PT; Ma J; Li HJ; Li GL; Han BH; Yuan CG
Acta Pharmacol Sin; 2012 Oct; 33(10):1311-8. PubMed ID: 22941289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
